This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Towa Pharmaceutical Completes Payment for Director Stock Compensation MT
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors CI
Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Towa Pharmaceutical Co., Ltd. completed the acquisition of Sunsho Pharmaceutical Co., Ltd. from Carlyle Japan Partners III, a fund managed by The Carlyle Group Inc. (NasdaqGS:CG). CI
Towa Pharmaceutical Co., Ltd. agreed to acquire Sunsho Pharmaceutical Co., Ltd. from Carlyle Japan Partners III, a fund managed by The Carlyle Group Inc. (NasdaqGS:CG) for ¥47.7 billion. CI
Protosera, Inc. announced that it expects to receive funding from Towa Pharmaceutical Co., Ltd. CI
Luye Pharma : Strikes Licensing Deal with Japan's Towa Pharma for Alzheimer's Disease Drug MT
Luye Pharma Switzerland AG and Towa Pharmaceutical Co., Ltd. Enters Strategic Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan CI
Towa Pharmaceutical Co., Ltd. completed the acquisition of Pensa Investments S.L. from Esteve Pharmaceuticals, S.A. CI
Innophys Co., Ltd. announced that it has received ¥3.53 billion in funding from a group of investors CI
Towa Pharmaceutical Co., Ltd. signed an agreement to acquire Pensa Investments S.L. from Esteve Pharmaceuticals, S.A. CI
Innophys Co., Ltd. announced that it expects to receive funding from Hi-Lex Corporation CI
Towa Pharmaceutical Co., Ltd. Announces Earnings Results for the Second Quarter of Fiscal Year 2016; Provides Earnings Guidance for the Full Year Ending March 2016; Revises Capital Expenditure Guidance for the Year Endings March 2017 and 2018 CI
Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter Ended December 2015; Reaffirms Earnings Guidance for the Full Year Ending March 2016 CI
Certain common shares of Towa Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 19-JAN-2016. CI
Tranche Update on Towa Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 7, 2015. CI
Towa Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 7, 2015, has expired with repurchase of 592,000 shares, representing 3.48% for ¥4,999.53 million. CI
Towa Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Towa Pharmaceutical Co., Ltd. announces an Equity Buyback for 700,000 shares, representing 4.12% for ¥5,000 million. CI
Towa Pharmaceutical Co., Ltd. Announces Earnings Results for the Second Quarter of Fiscal Year 2015; Provides Earnings Guidance for the Full Year Ending March 2015 CI
Towa Pharmaceutical Co. Ltd. Reports Earnings Results for the Third Quarter of the Year Ending March 2014; Revised Earnings Guidance for Year Ending March, 2014 CI
Towa Pharmaceutical Co. Ltd. Announces Consolidated and Non-Consolidated Earnings Results for the First Quarter Ended June 30, 2012; Provides Earnings Guidance for the Second Quarter of Fiscal 2013 CI
Towa Pharmaceutical Co. Ltd. Reports Consolidated and Non Consolidated Earnings Results for the Year Ended March 2012; Revised Earnings Guidance for the Year Ending March 2013 CI
Towa Pharmaceutical Co. Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Third Quarter of 2011; Reaffirms Earnings Guidance for the Year Ending March, 2012 CI
Chart Towa Pharmaceutical Co., Ltd.
More charts
Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2,773 JPY
Average target price
3,690 JPY
Spread / Average Target
+33.07%
Consensus
  1. Stock Market
  2. Equities
  3. 4553 Stock
  4. News Towa Pharmaceutical Co., Ltd.
  5. Towa Pharmaceutical Completes Payment for Director Stock Compensation